Wolfe Research initiated coverage of Centessa (CNTA) with an Outperform rating and $40 price target citing the firm’s “high-conviction” in lead asset ORX750.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals CEO Transition to Advisory Role Finalized
- Centessa management to meet with Piper Sandler
- Centessa price target raised to $38 from $33 at Truist
- Expanding Beyond Sleep: Buy Rating on Centessa Pharmaceuticals Driven by Compelling Preclinical Data for Orexin Agonist CNT-9982
- Centessa price target raised to $33 from $30 at Truist